Abstract
Arrowhead Pharmaceuticals will release quarterly results on May 7, 2026 Post Market; this preview summarizes consensus revenue, profitability and EPS expectations, reviews last quarter’s performance and business mix, and compiles the prevailing institutional stance alongside the factors most likely to shape the print and immediate stock reaction.Market Forecast
Based on current-quarter forecasts, Arrowhead Pharmaceuticals is expected to deliver revenue of 75.69 million US dollars, implying a 153.09% year-over-year rise, with an estimated adjusted EPS of -1.19 and EBIT of -177.37 million US dollars; year-over-year growth rates for EPS and EBIT are -499.63% and -356.25%, respectively. Margin forecasts are not disclosed, but the setup implies heavier operating spend or lower high-margin collaboration recognition relative to the prior quarter, resulting in a projected near-term loss.The company’s revenue is primarily driven by collaboration and licensing activities, which tend to be recognized episodically; partner-driven milestone timings remain the key swing factor for quarterly topline variability. The most promising revenue stream in the recent mix has been the Sarepta collaboration, which contributed 696.80 million US dollars in the latest reported period; year-over-year growth by segment was not provided, though the total revenue growth of 10,461.32% last quarter underscores the magnitude of collaboration-driven uplift.
Last Quarter Review
In the previous quarter, Arrowhead Pharmaceuticals reported revenue of 264.03 million US dollars, a gross profit margin of 100.00%, GAAP net profit attributable to the parent of 30.81 million US dollars with a net profit margin of 11.67%, and adjusted EPS of 0.22; year over year, revenue increased by 10,461.32% and adjusted EPS increased by 115.83%. Quarter on quarter, net profit rose by 229.73%, reflecting the outsized impact of high-margin collaboration revenue recognized in the period.A key financial highlight was the high gross margin profile—100.00%—reflecting that recognized revenue was largely from collaboration and licensing streams with minimal cost of goods sold in the period. Main business highlights reveal a revenue mix led by the Sarepta collaboration at 696.80 million US dollars, followed by Sanofi at 130.00 million US dollars and global service provider revenue of 2.65 million US dollars; while year-over-year segment growth was not provided, the mix illustrates the concentration of near-term revenue recognition in partnered programs.
Current Quarter Outlook
Main business: Collaboration revenue cadence and operating spend trajectory
The principal driver for Arrowhead Pharmaceuticals around this print is the cadence of collaboration and license revenue, which can be lumpy quarter to quarter. Consensus modeling for the current quarter points to 75.69 million US dollars in revenue, far below the prior quarter’s 264.03 million US dollars, which implicitly assumes lower milestone and upfront recognition in the period. This is paired with a projected adjusted EPS of -1.19 and EBIT of -177.37 million US dollars, both deeper on a year-over-year basis, suggesting that operating expenses—particularly R&D and SG&A tied to advancing clinical programs and preparing for commercial activities—will outweigh near-term revenue contributions.Given the company’s revenue recognition patterns, investors should pay close attention to any updates on partner program timelines that could trigger development or regulatory milestones. If management indicates a shift of expected milestone receipts into the following quarter or fiscal period, it would likely validate consensus assumptions for a loss-making quarter even with a 153.09% year-over-year topline increase from a small base in the year-ago period. Conversely, any earlier-than-expected milestone recognition would provide positive revenue surprise potential, but this is inherently dependent on partner progress and timing, not on steady-state product sales.
Margin dynamics will also be in focus. Last quarter’s 100.00% gross margin reflected a revenue mix dominated by high-margin collaboration items; if current quarter revenue again skews toward milestones and upfronts, gross margin could remain structurally high, but operating margin would still compress given the elevated investment phase. As a result, the primary determinant of bottom-line volatility this quarter is the scale and timing of non-cash and cash operating expenses relative to recognized collaboration revenue.
Most promising business: Sarepta collaboration as the fulcrum for near-term variability
Within the revenue mix, the Sarepta collaboration contributed 696.80 million US dollars in the latest reported period, making it the largest single revenue stream and a focal point for near-term catalysts. Although year-over-year growth for this segment was not disclosed, the absolute scale underscores its importance to recognized revenue and investor expectations. Milestone recognition from this collaboration is both episodic and material; therefore, even a small timing shift can translate into meaningful sequential changes in reported revenue and profits.For the current quarter, the base case implied by consensus appears to be limited Sarepta-related milestone recognition relative to last quarter’s outsized contribution. That conservatism sets up a classic “timing risk” scenario around the print: confirmation that larger milestones fall outside the quarter would reinforce the forecasted loss trajectory, while any indication of in-quarter recognition could provide upside. Beyond the mechanics of revenue recognition, investors should look for commentary on the subsequent quarter’s visibility, as it can recalibrate expectations faster than current-quarter results themselves.
The broader implication for valuation is that while high-margin collaboration revenue can amplify profitability when it lands, it does not necessarily provide a smooth quarterly earnings path. Clarity on the SAR-related development milestones and potential regulatory events would enhance confidence in the medium-term revenue bridge, even if this quarter’s numbers reflect a trough-like pattern following last quarter’s elevated recognition. Any management color on the expected cadence for the remainder of the fiscal year will likely be a major stock driver.
Key stock-price drivers this quarter: Guidance updates, opex intensity, and sentiment around the pipeline
Three factors appear most likely to dictate near-term stock performance. First, the direction and specificity of management’s commentary on revenue timing and the remainder-of-year cadence can either validate or challenge the market’s current path toward a more loss-heavy spring quarter. Even absent a granular numerical guide, qualitative markers about partner milestone schedules and the expected weighting of revenue across coming quarters will shape how investors extrapolate beyond this print.Second, operating expense intensity and its trajectory remain critical. The forecasted EBIT of -177.37 million US dollars points to a period of heavy investment, and the delta between R&D/SG&A outlays and recognized revenue will determine how negative adjusted EPS lands. Any indication of cost phasing—such as trial initiations, expansion cohorts, or commercial readiness spending—could alter margin expectations for subsequent quarters. If management signals that spending is front-loaded and likely to normalize later in the year, the negative EPS impact this quarter may be discounted; if spending is set to accelerate further, the market may extend caution on near-term profitability.
Third, sentiment around the clinical pipeline can amplify or dampen the earnings reaction, even when pipeline events are not directly revenue-generating this quarter. Recent attention to the company’s metabolic programs, including obesity-related approaches such as ARO-INHBE and ARO-ALK7, has heightened the focus on how upcoming clinical milestones could translate into future partnering or commercialization options. While those programs are not expected to contribute materially to the current quarter’s revenue, positive development commentary can offset near-term financial headwinds by supporting a stronger multi-quarter narrative. Conversely, if the update offers limited visibility on upcoming catalytic readouts, investors may focus more squarely on the near-term loss profile implied by consensus.
Analyst Opinions
Across institutional commentary tracked in the period from January 1, 2026 to April 30, 2026, the ratio of bullish to bearish views skews decisively bullish. Notably, Morgan Stanley upgraded Arrowhead Pharmaceuticals to Overweight with a price target increase to 100 US dollars from 78 US dollars in April, citing a more constructive outlook and improved risk-reward as the company progresses through a catalyst-rich phase. In addition, H.C. Wainwright reiterated a Buy rating during the period, reinforcing the thesis that the share price can absorb near-term earnings variability given anticipated program milestones and partnership dynamics.The majority-bullish stance hinges on several points that intersect directly with this quarter’s setup. First, analysts emphasize the high-quality nature of collaboration revenue and its propensity to deliver high gross margins when recognized; while this does not ensure steady quarterly profitability, it supports a valuation framework that looks through periods of heavier investment. This aligns with consensus forecasts showing a loss this quarter, even as revenue is expected to rise year over year by 153.09% from a small base, reinforcing that earnings volatility is dominated by timing rather than demand.
Second, the upgrade and reiterated Buy converge on the idea that a pipeline advancing through meaningful clinical and regulatory steps can reset revenue trajectories beyond the quarter under review. This is a core reason the majority view remains constructive even as the consensus embeds an adjusted EPS of -1.19 and EBIT of -177.37 million US dollars for the current quarter. Analysts in the bullish cohort characterize such a loss-making quarter as part of a broader investment cycle where operating expenses precede milestone and product revenue inflections; they look for management’s commentary to firm up the revenue bridge for the rest of the fiscal year, especially as it pertains to partner-driven receipts.
Third, supporters also point to the prior quarter’s performance—revenue of 264.03 million US dollars, 100.00% gross margin, and adjusted EPS of 0.22—as proof that when milestones align, the operating model can quickly convert into profitability. This context provides a backdrop for treating the current quarter’s expected losses as episodic rather than structural. The bullish case, therefore, is not predicated on beating near-term consensus, but on reinforcing a cadence of catalysts that can trigger future high-margin revenue recognition and improve visibility on the path to sustained profitability.
In this light, the predominant institutional view ahead of the May 7, 2026 Post Market release is supportive. Even if results come in broadly consistent with forecasts—revenue around 75.69 million US dollars and a negative adjusted EPS near -1.19—positive guidance on the timing of upcoming milestones or an improved spending trajectory could be sufficient to maintain or extend the constructive sentiment. Conversely, a lack of clarity on revenue cadence for the second half of the fiscal year would likely temper near-term enthusiasm, but the balance of current opinions suggests investors are prepared to evaluate the quarter within a multi-quarter framework driven by partner progress and pipeline readouts.
Comments